Intracoronary administration of anisodamine and nicorandil in individuals undergoing primary percutaneous coronary intervention for acute inferior myocardial infarction: A randomized factorial trial

Chen,Chunhong; Fu,Xianghua; Li,Wei; Jia,Xinwei; Bai,Shiru; Geng,Wei; Xing,Kun

doi:10.3892/etm.2015.2623

Intracoronary administration of anisodamine and nicorandil in individuals undergoing primary percutaneous coronary intervention for acute inferior myocardial infarction: A randomized factorial trial

Authors:
- Chunhong Chen
- Xianghua Fu
- Wei Li
- Xinwei Jia
- Shiru Bai
- Wei Geng
- Kun Xing
View Affiliations

Affiliations: Department of Cardiology, Second Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, P.R. China, Department of Cardiology, The Affiliated Hospital of Hebei University, Baoding, Hebei 071000, P.R. China
Published online on: July 7, 2015 https://doi.org/10.3892/etm.2015.2623
Pages: 1059-1065

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In acute inferior myocardial infarction (AIMI), numerous conventional drugs that are used to improve the myocardial microcirculation can significantly reduce blood pressure (BP) and coronary perfusion pressure, aggravate bradyarrhythmia and cause a deterioration in the hemodynamic state of the whole body, which greatly limits the application of these drugs in clinical settings. The aim of the present study was to assess the effect of anisodamine and nicorandil regimens on the prevention of no‑reflow (NR) and the amelioration of myocardial reperfusion in patients with AIMI undergoing primary percutaneous coronary intervention (PCI). A total of 104 consecutive patients with AIMI were included in this study and randomly assigned to one of four groups: A (control group), B (anisodamine group), C (nicorandil group) and D (anisodamine and nicorandil group). Patients underwent PCI via transradial artery access and the angiographic results were evaluated. Coronary diastolic BP (DBP) and systolic and mean BPs were measured by invasive catheterization. The primary end‑point was a post‑PCI Thrombolysis In Myocardial Infarction (TIMI) myocardial perfusion grade (TMPG) of 3. Composite end‑points (mortality + new MI + target vessel revascularization) were evaluated during the hospital stay and 30 days after discharge. Following the procedure, the proportion of patients achieving TMPG 3 was significantly higher in group D than that in the other groups (P=0.014); furthermore, the incidence of a postprocedural TIMI score of 3 was the highest in group D. Three days after the procedure, the peak creatine kinase‑MB and cardiac troponin I levels were the lowest and the left ventricular ejection fraction was the highest in group D. A thrombus score of 3/4 and low DBP were the independent risk factors for poor myocardial reperfusion (expressed as TMPG <3), while 2 mg anisodamine plus 2 mg nicorandil prior to PCI was protective for optimal myocardial reperfusion following the procedure. The combination of anisodamine and nicorandil can effectively ameliorate myocardial reperfusion and protect cardiac function in patients with AIMI undergoing primary PCI.

View Figures

View References

1	Niccoli G, Burzotta F, Galiuto L and Crea F: Myocardial no-reflow in humans. J Am Coll Cardiol. 54:281–292. 2009. View Article : Google Scholar : PubMed/NCBI
2	Zhao YJ, Fu XH, Ma XX, Wang DY, Dong QL, Wang YB, Li W, Xing K, Gu XS and Jiang YF: Intracoronary fixed dose of nitroprusside via thrombus aspiration catheter for the prevention of the no-reflow phenomenon following primary percutaneous coronary intervention in acute myocardial infarction. Exp Ther Med. 6:479–484. 2013.PubMed/NCBI
3	Chan W, Stub D, Clark DJ, Ajani AE, Andrianopoulos N, Brennan AL, New G, Black A, Shaw JA, Reid CM, et al: Melbourne Interventional Group Investigators: Usefulness of transient and persistent no reflow to predict adverse clinical outcomes following percutaneous coronary intervention. Am J Cardiol. 109:478–485. 2012. View Article : Google Scholar : PubMed/NCBI
4	Svilaas T, Vlaar PJ, van der Horst IC, Diercks GF, de Smet BJ, van den Heuvel AF, Anthonio RL, Jessurun GA, Tan ES, Suurmeijer AJ and Zijlstra F: Thrombus aspiration during primary percutaneous coronary intervention. N Engl J Med. 358:557–567. 2008. View Article : Google Scholar : PubMed/NCBI
5	Berger PB and Ryan TJ: Inferior myocardial infarction. High-risk subgroups. Circulation. 81:401–411. 1990. View Article : Google Scholar : PubMed/NCBI
6	Fu XH, Fan WZ, Gu XS, Wei YY, Jiang YF, Wu WL, Li SQ, Hao GZ, Wei QM and Xue L: Effect of intracoronary administration of anisodamine on slow reflow phenomenon following primary percutaneous coronary intervention in patients with acute myocardial infarction. Chin Med J (Engl). 120:1226–1231. 2007.PubMed/NCBI
7	Wang Y, Fu X, Wang X, Jia X, Gu X, Zhang J, Su J, Hao G, Jiang Y, Fan W, et al: Protective effects of anisodamine on renal function in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Tohoku J Exp Med. 224:91–97. 2011. View Article : Google Scholar : PubMed/NCBI
8	Geng W, Fu XH, Gu XS, Wang YB, Wang XC, Li W, Jiang YF, Hao GZ, Fan WZ and Xue L: Preventive effects of anisodamine against contrast-induced nephropathy in type 2 diabetics with renal insufficiency undergoing coronary angiography or angioplasty. Chin Med J (Engl). 125:3368–3372. 2012.PubMed/NCBI
9	Wang YB, Fu XH, Gu XS, Wang XC, Zhao YJ, Hao GZ, Jiang YF, Fan WZ, Wu WL, Li SQ and Xue L: Safety and efficacy of anisodamine on prevention of contrast induced nephropathy in patients with acute coronary syndrome. Chin Med J (Engl). 125:1063–1067. 2012.PubMed/NCBI
10	Lee HC, An SG, Choi JH, Lee TK, Kim J, Kim JH, Chun KJ, Hong TJ, Shin YW and Lee SK: Effect of intra-coronary nicorandil administration prior to reperfusion in acute ST segment elevation myocardial infarction. Circ J. 72:1425–1429. 2008. View Article : Google Scholar : PubMed/NCBI
11	Ota S, Nishikawa H, Takeuchi M, Nakajima K, Nakamura T, Okamoto S, Setsuda M, Makino K, Yamakado T and Nakano T: Impact of nicorandil to prevent reperfusion injury in patients with acute myocardial infarction: Sigmart Multicenter Angioplasty Revascularization Trial (SMART). Circ J. 70:1099–1104. 2006. View Article : Google Scholar : PubMed/NCBI
12	Ikeda N, Yasu T, Kubo N, Hashimoto S, Tsuruya Y, Fujii M, Kawakami M and Saito M: Nicorandil versus isosorbide dinitrate as adjunctive treatment to direct balloon angioplasty in acute myocardial infarction. Heart. 90:181–185. 2004. View Article : Google Scholar : PubMed/NCBI
13	TIMI Study Group, . The Thrombolysis In Myocardial Infarction(TIMI) trial. Phase I findings. TIMI Study Group. N Engl J Med. 312:932–936. 1985. View Article : Google Scholar : PubMed/NCBI
14	Gibson CM, Cannon CP, Murphy SA, Ryan KA, Mesley R, Marble SJ, McCabe CH, Van De Werf F and Braunwald E: Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation. 101:125–130. 2000. View Article : Google Scholar : PubMed/NCBI
15	Kawai Y, Hisamatsu K, Matsubara H, Dan K, Akagi S, Miyaji K, Munemasa M, Fujimoto Y, Kusano KF and Ohe T: Intravenous administration of nicorandil immediately before percutaneous coronary intervention can prevent slow coronary flow phenomenon. Eur Heart J. 30:765–772. 2009. View Article : Google Scholar : PubMed/NCBI
16	Shen J, Zhang Q, Zhang RY, Zhang JS, Hu J, Yang ZK, Zheng AF, Zhang X and Shen WF: Clinical benefits of adjunctive tirofiban therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Coron Artery Dis. 19:271–277. 2008. View Article : Google Scholar : PubMed/NCBI
17	Huber K, Holmes DR Jr, van't Hof AW, Montalescot G, Aylward PE, Betriu GA, Widimsky P, Westerhout CM, Granger CB and Armstrong PW: Use of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention: Insights from the APEX-AMI trial. Eur Heart J. 31:1708–1716. 2010. View Article : Google Scholar : PubMed/NCBI
18	Gibson CM, de Lemos JA, Murphy SA, et al: TIMI Study Group: Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: A TIMI 14 substudy. Circulation. 103:2550–2554. 2001. View Article : Google Scholar : PubMed/NCBI
19	Rezkalla SH and Kloner RA: No-reflow phenomenon. Circulation. 105:656–662. 2002. View Article : Google Scholar : PubMed/NCBI
20	Reffelmann T and Kloner RA: The ‘no-reflow’ phenomenon: Basic science and clinical correlates. Heart. 87:162–168. 2002. View Article : Google Scholar : PubMed/NCBI
21	Galiuto L: Optimal therapeutic strategies in the setting of post-infarct no reflow: The need for a pathogenetic classification. Heart. 90:123–125. 2004. View Article : Google Scholar : PubMed/NCBI
22	Niccoli G, Lanza GA, Shaw S, Romagnoli E, Gioia D, Burzotta F, Trani C, Mazzari MA, Mongiardo R, De Vita M, et al: Endothelin-1 and acute myocardial infarction: A no-reflow mediator after successful percutaneous myocardial revascularization. Eur Heart J. 27:1793–1798. 2006. View Article : Google Scholar : PubMed/NCBI
23	Xiu RJ, Hammerschmidt DE, Coppo PA and Jacob HS: Anisodamine inhibits thromboxane synthesis, granulocyte aggregation, and platelet aggregation. A possible mechanism for its efficacy in bacteremic shock. JAMA. 247:1458–1460. 1982. View Article : Google Scholar : PubMed/NCBI
24	Zhao B, Li J, Luo X, Zhou Q, Chen H and Shi H: The role of von Willebrand factor and ADAMTS13 in the no-reflow phenomenon: After primary percutaneous coronary intervention. Tex Heart Inst J. 38:516–522. 2011.PubMed/NCBI
25	Matsumoto H, Inoue N, Takaoka H, Hata K, Shinke T, Yoshikawa R, Masai H, Watanabe S, Ozawa T and Yokoyama M: Depletion of antioxidants is associated with no-reflow phenomenon in acute myocardial infarction. Clin Cardiol. 27:466–470. 2004. View Article : Google Scholar : PubMed/NCBI
26	Wang A, Chen F, Xie Y, Guo Z and Yu Y: Protective mechanism of nicorandil on rat myocardial ischemia-reperfusion. J Cardiovasc Med (Hagerstown). 13:511–515. 2012. View Article : Google Scholar : PubMed/NCBI
27	Iwakura K: Modulation of individual susceptibility to the no-reflow phenomenon after acute myocardial infarction. Curr Pharm Des. 19:4519–4528. 2013. View Article : Google Scholar : PubMed/NCBI
28	Akai K, Wang Y, Sato K, Sekiguchi N, Sugimura A, Kumagai T, Komaru T, Kanatsuka H and Shirato K: Vasodilatory effect of nicorandil on coronary arterial microvessels: Its dependency on vessel size and the involvement of the ATP-sensitive potassium channels. J Cardiovasc Pharmacol. 26:541–547. 1995. View Article : Google Scholar : PubMed/NCBI